DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Arimidex (Anastrozole) - Summary



ARIMIDEX® (anastrozole) tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor.

ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

The effectiveness of ARIMIDEX in early breast cancer is based on an analysis of recurrence-free survival in patients treated for a median of 31 months (see CLINICAL PHARMACOLOGY -- Clinical Studies subsection). Further follow-up of study patients will be required to determine long-term outcomes.

ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.

ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.

See all Arimidex indications & dosage >>


Media Articles Related to Arimidex (Anastrozole)

Many Women With Breast Cancer Can't Afford Their Drugs
Source: Medscape Hematology-Oncology Headlines [2015.11.27]
Hormonal therapy saves lives of women with breast cancer, yet many low-income women, especially if they lack prescription drug coverage, are unable to afford it.
Medscape Medical News

Targeting IL13Ralpha2 to Suppress Breast Cancer Lung Metastasis
Source: Medscape Pathology & Lab Medicine Headlines [2015.11.27]
Learn more about novel genes that drive metastasis of BLBC and elucidate the underlying mechanisms of action.
Breast Cancer Research

Antibody-drug compounds and immunotherapy to treat breast cancer
Source: Breast Cancer News From Medical News Today [2015.11.26]
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.

Nurse Navigators and Timely Genomic Testing in Breast Cancer
Source: Medscape Pathology & Lab Medicine Headlines [2015.11.25]
Genomic testing has become the standard of care for patients with early-stage breast cancer. Nurse navigators can play a key role in facilitating timely access to genomic profiling.
Clinical Journal of Oncology Nursing

Preventing Cardiac Dysfunction During Breast Cancer Therapy
Source: theheart.org | Medscape Cardiology Headlines [2015.11.24]
Dr John Mandrola sits down with Dr Geeta Gulati and Dr Torbjorn Omland to discuss the late-breaking PRADA trial from the American Heart Association sessions.
theheart.org on Medscape

more news >>

Published Studies Related to Arimidex (Anastrozole)

Lipid profiles within the SABRE trial of anastrozole with and without risedronate. [2012]
Lipid profiles in women with early breast cancer receiving anastrozole with or without risedronate were examined within an international Phase III/IV study to assess for possible treatment related changes. Postmenopausal women with hormone receptor-positive breast cancer were assigned to 1 of 3 strata by risk of fragility fracture...

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. [2012]
Weight gain is commonly reported by breast cancer patients on tamoxifen or aromatase inhibitors. Since weight gain may impact on outcome and compliance we have prospectively assessed the effects of these agents on weight change in three randomised trials for the treatment or prevention of breast cancer...

Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence, crossover study. [2012]
formulations in healthy male adult volunteers... CONCLUSION: The test and reference formulations had similar PK parameters and

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. [2012]
goserelin for early breast cancer in the neoadjuvant setting... INTERPRETATION: Given its favourable risk-benefit profile, the combination of

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. [2011.06.10]
PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations... CONCLUSION: Neoadjuvant AI treatment markedly improved surgical outcomes. Ki67 and PEPI data demonstrated that the three agents tested are biologically equivalent and therefore likely to have similar adjuvant activities. LumA tumors were more likely to have favorable biomarker characteristics after treatment; however, occasional paradoxical increases in Ki67 (12% of tumors with > 5% increase after therapy) suggest treatment-resistant cells, present in some LumA tumors, can be detected by post-treatment profiling.

more studies >>

Clinical Trials Related to Arimidex (Anastrozole)

Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer [Active, not recruiting]
Over the last 3 decades, a steady shift has occurred in the management of breast cancer. Because it was traditionally viewed as a local disease, many advocated the use of radical surgery to achieve maximum survival benefit. This view has been slowly replaced by a broader biologic view that recognizes the often systemic nature of breast cancer, even when it appears to be localized to the breast. Results from randomized clinical trials have demonstrated that less extensive surgery, or lumpectomy plus radiation therapy, are optimal for local management of early breast cancer. In addition to the less radical approach to surgical treatment of breast cancer, other randomized clinical trials have established the value of postoperative systemic therapy in improving overall survival by eradicating micrometastatic disease, the major cause of mortality from breast cancer. Despite the well-documented benefits of adjuvant systemic therapy, it is not effective in preventing death from breast cancer in all patients who are candidates for such treatment. The worth of such therapy can only be judged in retrospect upon disease relapse, a time when breast cancer is nearly always incurable. Currently, there are few reliable methods to predict the success or failure of a particular postoperative treatment modality, and better ways to predict and optimize outcome are needed. Combination endocrine therapy: Using endocrine agents with different mechanisms of action together has the potential advantage of more effectively blocking ER signaling, thus improving the efficacy of such agents against breast cancer. In the past, attempts to combine endocrine agents for ER-positive breast cancer have had mixed results, depending on the setting and the patient population studied. Endocrine agents without any agonist effect could potentially be used in combination with aromatase inhibitors, under the rationale that the combination would maximally blockade estrogen receptor signaling, thus potentially improving the antitumor effect. Fulvestrant (FASLODEX) is a pure estrogen antagonist with no known agonist effect; thus, it has the potential to provide additional benefit when combined with an aromatase inhibitor. This concept provides the rationale for using the combination of anastrazole and fulvestrant in this study.

Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects [Completed]
This study is to investigate whether anastrozole ODF is bioequivalent with Arimidex tablet after a single oral administration of each anastrozole formulation.

Liver Safety Under Upfront Arimidex vs Tamoxifen [Completed]
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases. The second objectives are to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidences of abnormal liver function test, and time to treatment failure.

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. [Active, not recruiting]
The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid [Active, not recruiting]
The primary objective is, first, the comparison of tamoxifen and anastrozole and, second, the comparison of zoledronate added to standard adjuvant therapy with controls according to disease-free survival (DFS) in premenopausal patients with non-metastatic breast cancer treated with tamoxifen or anastrozole. To assess whether zoledronate added to standard adjuvant therapy can decrease or even prevent bone loss in patients treated with hormonal blockade combined with an antiestrogen or aromatase inhibitor.

more trials >>

Reports of Suspected Arimidex (Anastrozole) Side Effects

Arthralgia (123)Neoplasm Malignant (113)Malaise (86)Hot Flush (79)Breast Cancer (78)Pain in Extremity (67)Fall (66)Drug Dose Omission (63)Fatigue (58)Alopecia (56)more >>


Based on a total of 1 ratings/reviews, Arimidex has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.

Arimidex review by 45 year old female patient

Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   post breast cancer
Dosage & duration:   1mg taken once a day for the period of 5 years
Other conditions:   none
Other drugs taken:   none
Reported Results
Benefits:   Considered beneficial for post menapausal women to prevent the recurrance of breast cancer. It is a hormone blocker that stops the production of estrogen. Many breast cancer tumors are estrogen positive and thrive in the presence of estrogen.
Side effects:   I had no side effects but possible side effects are, constipation, headaches, nausea, diahrea, weight gain.
Comments:   One 1mg pill once a day for five years following treatment of breast cancer in post menapausal women.

See all Arimidex reviews / ratings >>

Page last updated: 2015-11-27

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015